Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies
Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.
You may also be interested in...
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
Investors continue to focus on anticancer therapies including small molecule drugs and cell therapies in China.
The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.